InvestorsHub Logo
Followers 2
Posts 1798
Boards Moderated 0
Alias Born 01/05/2017

Re: None

Wednesday, 08/01/2018 10:39:56 AM

Wednesday, August 01, 2018 10:39:56 AM

Post# of 108192
Ken Berlin's statement on phase 3 AIM2CERV trail:

"If no partner emerges, we will wind down the ongoing AIM2CERV trial in high-risk locally advanced cervical cancer, and we will not conduct the ADVANCE PD-1 combination trial in metastatic cervical cancer, which you may recall is not yet been initiated. We have given ourselves a limited period of time to secure a partner. We intend to provide an update on this program during our 3Q call."

Source:
https://seekingalpha.com/article/4180173-advaxis-inc-adxs-ceo-ken-berlin-q2-2018-results-earnings-call-transcript
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News